ArticleProceedings of the National Academy of Sciences of the United States of America2009
Subregional neuroanatomical change as a biomarker for Alzheimer's disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 137 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed.
- Differential Effects of Physical Exercise, Cognitive Training, and Mindfulness Practice on Serum BDNF Levels in Healthy Older Adults: A Randomized Controlled Intervention Study.Journal of Alzheimer's disease : JAD · 2019Trial
- Individual classification of mild cognitive impairment subtypes by support vector machine analysis of white matter DTI.AJNR. American journal of neuroradiology · 2013Trial
- Trial
- Boosting power for clinical trials using classifiers based on multiple biomarkers.Neurobiology of aging · 2010Trial
- Feasibility of High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumor and Young Adults With Isocitrate Dehydrogenase-Mutant Gliomas (HYPE): Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Mapping heterogeneous brain structural subtypes in alzheimer's disease and mild cognitive impairment using normative models.Translational psychiatry · 2026Article
- The heat exposure, aging trajectories, and Alzheimer's disease (HEAT-AD) study protocol.PloS one · 2026Article
- Prognostic model for predicting Alzheimer's disease conversion using functional connectome manifolds.Alzheimer's research & therapy · 2024Article
- Progressive cervical cord atrophy parallels cognitive decline in Alzheimer's disease.Scientific reports · 2024Article
- Neurofibrillary tangle-bearing neurons have reduced risk of cell death in mice with Alzheimer's pathology.Cell reports · 2024Article
- Regional deep atrophy: Using temporal information to automatically identify regions associated with Alzheimer's disease progression from longitudinal MRI.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Omega-3 Fatty Acids, Cognition, and Brain Volume in Older Adults.Brain sciences · 2023Article
- Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2023Article
- Restriction spectrum imaging with elastic image registration for automated evaluation of response to neoadjuvant therapy in breast cancer.Frontiers in oncology · 2023Article
- New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol.BMJ open · 2022Article
- Increased regional white matter hyperintensity volume in objectively-defined subtle cognitive decline and mild cognitive impairment.Neurobiology of aging · 2022Article
- Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.Metabolic brain disease · 2022Review
- Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors (The AIM Trial): Rationale, Design, and Methods.Frontiers in oncology · 2022Article
- Reducing Metabolic Dysregulation in Obese Latina and/or Hispanic Breast Cancer Survivors Using Physical Activity (ROSA) Trial: A Study Protocol.Frontiers in oncology · 2022Article
- Structural MRI Reveals Cervical Spinal Cord Atrophy in the P301L Mouse Model of Tauopathy: Gender and Transgene-Dosing Effects.Frontiers in aging neuroscience · 2022Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedFenema-Notestine, Christine [corrected to Fennema-Notestine, Christine]
Authors and funding
7 authors.
Funding
Abstract
Regions of the temporal and parietal lobes are particularly damaged in Alzheimer's disease (AD), and this leads to a predictable pattern of brain atrophy. In vivo quantification of subregional atrophy, such as changes in cortical thickness or structure volume, could lead to improved diagnosis and better assessment of the neuroprotective effects of a therapy. Toward this end, we have developed a fast and robust method for accurately quantifying cerebral structural changes in several cortical and subcortical regions using serial MRI scans. In 169 healthy controls, 299 subjects with mild cognitive impairment (MCI), and 129 subjects with AD, we measured rates of subregional cerebral volume change for each cohort and performed power calculations to identify regions that would provide the most sensitive outcome measures in clinical trials of disease-modifying agents. Consistent with regional specificity of AD, temporal-lobe cortical regions showed the greatest disease-related changes and significantly outperformed any of the clinical or cognitive measures examined for both AD and MCI. Global measures of change in brain structure, including whole-brain and ventricular volumes, were also elevated in AD and MCI, but were less salient when compared to changes in normal subjects. Therefore, these biomarkers are less powerful for quantifying disease-modifying effects of compounds that target AD pathology. The findings indicate that regional temporal lobe cortical changes would have great utility as outcome measures in clinical trials and may also have utility in clinical practice for aiding early diagnosis of neurodegenerative disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.